Cargando…

Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation

BACKGROUND: Previous studies have revealed the risk factors for femoral pseudoaneurysms (FPA). Most data on FPA are based on coronary and peripheral interventions, with limited studies focusing on atrial fibrillation (AF) ablation. However, patient backgrounds, anticoagulation regimens, and vascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Koyama, Takafumi, Tobita, Kazuki, Kawaguchi, Tatsuto, Uchida, Shuhei, Koyama, Eiji, Kodera, Nobuhisa, Tamaki, Yusuke, Otomaru, Yuri, Miyashita, Hirokazu, Yamashita, Takayoshi, Mizuno, Shingo, Murakami, Masato, Saito, Shigeru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692832/
https://www.ncbi.nlm.nih.gov/pubmed/38045461
http://dx.doi.org/10.1002/joa3.12950
_version_ 1785153028204003328
author Koyama, Takafumi
Tobita, Kazuki
Kawaguchi, Tatsuto
Uchida, Shuhei
Koyama, Eiji
Kodera, Nobuhisa
Tamaki, Yusuke
Otomaru, Yuri
Miyashita, Hirokazu
Yamashita, Takayoshi
Mizuno, Shingo
Murakami, Masato
Saito, Shigeru
author_facet Koyama, Takafumi
Tobita, Kazuki
Kawaguchi, Tatsuto
Uchida, Shuhei
Koyama, Eiji
Kodera, Nobuhisa
Tamaki, Yusuke
Otomaru, Yuri
Miyashita, Hirokazu
Yamashita, Takayoshi
Mizuno, Shingo
Murakami, Masato
Saito, Shigeru
author_sort Koyama, Takafumi
collection PubMed
description BACKGROUND: Previous studies have revealed the risk factors for femoral pseudoaneurysms (FPA). Most data on FPA are based on coronary and peripheral interventions, with limited studies focusing on atrial fibrillation (AF) ablation. However, patient backgrounds, anticoagulation regimens, and vascular access methods differ. In addition, a standard for managing FPA after AF ablation remains elusive due to the difficult nature of achieving thrombosis in pseudoaneurysms. METHODS: This single‐center, retrospective, observational study included 2805 consecutive patients who underwent AF ablation between January 2016 and December 2021. All patients underwent femoral artery and vein punctures. Puncture sites were checked 1 day post‐procedure. RESULTS: A total of 23 FPA patients were identified during the study period. Multivariate logistic regression analysis showed that hypertension (odds ratio 4.66, 95% confidence interval: 1.38–15.71; p = .0032) and warfarin use (odds ratio 3.83, 95% confidence interval: 1.40–10.45; p = .021) were significantly associated with the occurrence of FPA. The compression success rate was low (22%). There were nine and six patients in the endovascular treatment (EVT) and ultrasound‐guided thrombin injection (UGTI) groups, respectively. The success rates were 100% and 84% in the EVT and UGTI groups, respectively. The length of hospital stay after FPA treatment was 2.1 days in the EVT group and 1.3 days in the thrombin group. CONCLUSION: We must be careful about post‐procedural FPA, especially for hypertension and warfarin‐using patients. Treatment of pseudoaneurysms with anticoagulants is unlikely to achieve hemostasis, and an early switch to invasive treatments, such as EVT, should be considered.
format Online
Article
Text
id pubmed-10692832
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106928322023-12-03 Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation Koyama, Takafumi Tobita, Kazuki Kawaguchi, Tatsuto Uchida, Shuhei Koyama, Eiji Kodera, Nobuhisa Tamaki, Yusuke Otomaru, Yuri Miyashita, Hirokazu Yamashita, Takayoshi Mizuno, Shingo Murakami, Masato Saito, Shigeru J Arrhythm Original Articles BACKGROUND: Previous studies have revealed the risk factors for femoral pseudoaneurysms (FPA). Most data on FPA are based on coronary and peripheral interventions, with limited studies focusing on atrial fibrillation (AF) ablation. However, patient backgrounds, anticoagulation regimens, and vascular access methods differ. In addition, a standard for managing FPA after AF ablation remains elusive due to the difficult nature of achieving thrombosis in pseudoaneurysms. METHODS: This single‐center, retrospective, observational study included 2805 consecutive patients who underwent AF ablation between January 2016 and December 2021. All patients underwent femoral artery and vein punctures. Puncture sites were checked 1 day post‐procedure. RESULTS: A total of 23 FPA patients were identified during the study period. Multivariate logistic regression analysis showed that hypertension (odds ratio 4.66, 95% confidence interval: 1.38–15.71; p = .0032) and warfarin use (odds ratio 3.83, 95% confidence interval: 1.40–10.45; p = .021) were significantly associated with the occurrence of FPA. The compression success rate was low (22%). There were nine and six patients in the endovascular treatment (EVT) and ultrasound‐guided thrombin injection (UGTI) groups, respectively. The success rates were 100% and 84% in the EVT and UGTI groups, respectively. The length of hospital stay after FPA treatment was 2.1 days in the EVT group and 1.3 days in the thrombin group. CONCLUSION: We must be careful about post‐procedural FPA, especially for hypertension and warfarin‐using patients. Treatment of pseudoaneurysms with anticoagulants is unlikely to achieve hemostasis, and an early switch to invasive treatments, such as EVT, should be considered. John Wiley and Sons Inc. 2023-11-08 /pmc/articles/PMC10692832/ /pubmed/38045461 http://dx.doi.org/10.1002/joa3.12950 Text en © 2023 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Koyama, Takafumi
Tobita, Kazuki
Kawaguchi, Tatsuto
Uchida, Shuhei
Koyama, Eiji
Kodera, Nobuhisa
Tamaki, Yusuke
Otomaru, Yuri
Miyashita, Hirokazu
Yamashita, Takayoshi
Mizuno, Shingo
Murakami, Masato
Saito, Shigeru
Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation
title Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation
title_full Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation
title_fullStr Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation
title_full_unstemmed Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation
title_short Incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation
title_sort incidence, clinical course, and risk factors in the development of femoral pseudoaneurysm after atrial fibrillation ablation
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692832/
https://www.ncbi.nlm.nih.gov/pubmed/38045461
http://dx.doi.org/10.1002/joa3.12950
work_keys_str_mv AT koyamatakafumi incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation
AT tobitakazuki incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation
AT kawaguchitatsuto incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation
AT uchidashuhei incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation
AT koyamaeiji incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation
AT koderanobuhisa incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation
AT tamakiyusuke incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation
AT otomaruyuri incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation
AT miyashitahirokazu incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation
AT yamashitatakayoshi incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation
AT mizunoshingo incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation
AT murakamimasato incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation
AT saitoshigeru incidenceclinicalcourseandriskfactorsinthedevelopmentoffemoralpseudoaneurysmafteratrialfibrillationablation